EGFR and HER2 inhibition in pancreatic cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Pancreatic cancer remains a challenging disease with limited treatment options.
• Targeted therapies inhibiting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) are areas of interest.
• Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR and HER2.

Purpose of the Study:

• To evaluate the efficacy of lapatinib as a monotherapy and in combination with standard chemotherapies against pancreatic cancer cell lines.
• To assess the expression levels of EGFR and HER2 in pancreatic tumor specimens to identify potential patient populations for lapatinib therapy.

Main Methods:

• In vitro studies using pancreatic cancer cell lines (BxPc-3, HPAC) treated with lapatinib alone and in combination with gemcitabine, cisplatin, and 5'deoxy-5'fluorouridine.
• Drug effect and combination index (CI) isobologram analysis to determine drug interactions.
• Immunohistochemistry to analyze EGFR and HER2 expression in 72 pancreatic cancer tumor specimens.

Main Results:

• Lapatinib demonstrated significant anti-proliferative activity in sensitive cell lines (IC(50)<2 μM) and showed activity in erlotinib-resistant, K-Ras mutated cell lines.
• Combination therapy with lapatinib and chemotherapies exhibited concentration-dependent anti-proliferative effects.
• EGFR expression was detected in 44% of pancreatic tumors, while HER2 expression was found in only 1%.

Conclusions:

• Lapatinib exhibits anti-cancer effects on pancreatic cancer cell lines, both alone and in combination with chemotherapy.
• The observed EGFR expression in a significant subset of pancreatic tumors suggests potential clinical benefit of lapatinib in EGFR-positive pancreatic ductal adenocarcinoma.